Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bevacizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Henlius
Deal Size : $25.0 million
Deal Type : Licensing Agreement
Details : Pursuant to the Agreement, Essex and Henlius will co-develop the bevacizumab HLX04 for treatment of ophthalmic diseases such as exudative (wet) Age-related Macular Degeneration (wAMD).
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $10.0 million
October 15, 2020
Lead Product(s) : Bevacizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Henlius
Deal Size : $25.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Visomitin
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Recipient : Mitotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VISTA-2 is a multi-centre, randomized, double-blind, placebo-controlled clinical study involving two treatment arms: SkQ1 ophthalmic solution and vehicle solution, administered BID.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 25, 2020
Lead Product(s) : Visomitin
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Recipient : Mitotech
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
